Extended trial of Zevalin yields positive results

12/8/2008 | RTT News

An extended first-line indolent trial on Zevalin, Cell Therapeutics' radioimmunotherapy, found that patients with follicular B-cell non-Hodgkin's lymphoma who responded to first-line treatment exhibited continued improvement in progression-free survival after Zevalin consolidation therapy. The trial also showed that Zevalin consolidation treatment had no adverse effect on second-line therapies, including stem cell transplants among relapse patients.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY